Categories AlphaGraphs, Earnings, Health Care
AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%
AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%.
Net loss, excluding special items, was $0.04 per share in the November quarter, compared to a loss of $0.05 per share in the corresponding period of 2024. On an unadjusted basis, net loss narrowed to $10.7 million or $0.26 per share in Q2 from $29 million or $0.72 per share in the prior-year quarter.
Revenues, on a reported basis, decreased 8% year-over-year to $72.8 million in the second quarter. The company continues to expect fiscal 2025 sales in the range of $282 million to $288 million.
Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “We are very excited about our strong performance during the second quarter, and in particular the continued strength of our Med Tech segment,
which grew 25% over the prior year.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
LW Earnings: Key quarterly highlights from Lamb Weston’s Q3 2025 financial results
Lamb Weston Holdings, Inc. (NYSE: LW) reported its third quarter 2025 earnings results today. Net sales increased 4% to $1.52 billion compared to the same period a year ago. Net
CAG Earnings: Highlights of Conagra Brands’ Q3 2025 report
Conagra Brands, Inc. (NYSE: CAG), a leading provider of consumer packaged goods, reported a decrease in net sales and adjusted earnings for the third quarter of 2025. Net sales were
Fastenal Company (FAST) looks poised for a mixed start to FY25
Fastenal Company (NASDAQ: FAST) will report its first-quarter results on April 11, at 6:50 am ET. The company has been investing heavily to expand its digital footprint lately, and it
